OAOsama A Alzuman

Osama A Alzuman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Osama A Alzuman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Abdulaziz Ageel Alageel

    Microbiology Department, Pathology & Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh, Saudi Arabia

    1 shared publication
  • Abeer Odah AlMazyad

    Microbiology Department, Pathology & Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh, Saudi Arabia

    1 shared publication
  • Ahlam Alghamdi

    Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia

    1 shared publication
  • Ahmed A Alrashed

    Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia

    1 shared publication
  • Ahmed Rashed Alsaegh

    Department of Clinical Pharmacy, King Saud Medical City, Riyadh, Saudi Arabia

    1 shared publication
  • Alnada Ibrahim

    Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

    1 shared publication

Latest Publications

  • Open Access

    Clinical Characteristics, Antifungal Therapy, and Outcomes of Candida auris Candidemia: A Two-Center Cohort Study

    by Reem Binsuwaidan, Layan W Alshalhoub, Nada Mabruk Almesfer, Sara Almuhisen, Osama A Alzuman, Alnada Ibrahim, Yahya A Mohzari, Ahmed A Alrashed, Reem F Bamogaddam, Seham Elbih, et al.

    Background: Candida auris has become a growing concern in hospital settings because of its resistance to multiple antifungal drugs. This study investigated the clinical features, treatment patterns, and outcomes of patients diagnosed with C. auris candidemia at two medical centers in Riyadh, Saudi Arabia. Methods: A two centres, retrospective cohort study which includes adult patients who had positive blood cultures for C. auris. The analysis covered patient characteristics, antifungal treatments, and outcomes. Results: The cohort consisted of 228 cases with C. auris candidemia 51.4% of whom were male. The average age of patients was 61.9± 17.8 years, and common comorbidities included hypertension (59.2%) and diabetes (50.0%). ICU care was needed for 68.8% of the patients. Fluconazole resistance was high (77%), while echinocandins showed > 90% susceptibility. Patients who received monotherapy had faster clearance (median = 4; IQR = 3– 5) compared to combination therapy (median = 5; IQR = 3.75– 8) (p= 0.013). Fewer recurrences were observed in monotherapy (11.1%) compared to those on combination therapy (23.7%) (p= 0.021). Survival was significantly lower among patients with high SOFA scores (p=0.027). Conclusion: C. auris candidemia remains a major clinical challenge due to its drug resistance and the severity of illness in affected patients. Echinocandins continue to be the preferred first-line treatments, and using SOFA scores may help in predicting patient outcomes and guiding treatment plans.